SLAM
PTCT icon

Swiss Life Asset Management’s PTC Therapeutics PTCT Stock Holding History

Swiss Life Asset Management’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$630K Buy
7,729
+360
+5% +$26K ﹤0.01% 849
2026
Q1 		$502K Buy
7,369
+1,578
+27% +$112K ﹤0.01% 863
2025
Q4 		$440K Buy
+5,791
New +$421K ﹤0.01% 839

Other funds holding PTCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Swiss Life Asset Management's PTCT Position: Q2 2026 in Review

Swiss Life Asset Management increased its PTC Therapeutics (PTCT) stake by 4.9% in Q2 2026, buying an estimated $26K and bringing the position to 7,729 shares worth $630K. The position accounts for ﹤0.01% of the portfolio, ranked #849.

Swiss Life Asset Management first reported a position in PTCT in Q4 2025 and has held it in 3 quarters since. 231 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

  • Swiss Life Asset Management held 7,729 shares of PTC Therapeutics worth $630K as of Q2 2026.
  • Swiss Life Asset Management bought 360 PTC Therapeutics shares in Q2 2026, an estimated $26K.
  • PTC Therapeutics made up ﹤0.01% of Swiss Life Asset Management's portfolio in Q2 2026, its #849 holding.
  • Swiss Life Asset Management first reported a position in PTC Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 231 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on Swiss Life Asset Management's 13F filing for Q2 2026, filed 29 Jul 2026.